A study at EuroPCR 2016 found that half of transcatheter heart valves may undergo degeneration within 10 years after TAVI. The study, which followed 704 patients for up to 10 years, identified 35 cases of valve degeneration, with approximately two-thirds associated with intravalvular regurgitation.
The conference features research on mitral and tricuspid valve interventions, new devices for percutaneous coronary interventions, and approaches to treat heart failure and stroke. Key findings highlight the potential of TAVI for low-risk patients and the impact of recent trials on clinical practice.
New techniques and devices are being developed to treat heart failure, mitral valve regurgitation, and coronary artery lesions. Studies show high procedural success rates and improvements in heart function and quality of life.
EuroPCR 2015 highlighted the benefits of mechanical thrombectomy in acute stroke, showing significant improvement in outcomes for one-third of patients who qualify for the procedure. The meeting also showcased advancements in coronary interventions, including chronic total occlusions and stent thrombosis.
A large registry study found that patients experiencing stent thrombosis between 2-30 days post-procedure had higher mortality rates compared to those who developed the complication within 24 hours. The timing of stent thrombosis may be linked to more severe infarction and long-term heart failure.
A recent study presented at EuroPCR 2015 found that thickening of valve leaflets following TAVI or surgical aortic valve implantation is relatively rare and not linked to short-term clinical events. The study suggests that current TAVI and TAVR programs do not need modification, but further research is needed.
Dr. Ferdinand Kiemeneij and Dr. Shigeru Saito received the Ethica Award for their roles in developing and teaching the radial approach to coronary catheterization. They are internationally renowned for their contributions to interventional medicine, patient comfort, and quality of life.
A recent study presented at EuroPCR 2015 found that routine thrombectomy during angioplasty for acute myocardial infarction may increase the risk of stroke. The TOTAL trial showed a significant increase in stroke rates within 30 days, with the highest risk period being within 48 hours.
The European Clinical Consensus Conference concludes that research into renal denervation for high blood pressure should not be abandoned until high-quality research is completed according to agreed-upon standards. The group also emphasizes the need for standardization in treatments, populations, methods, and adherence measures.
Recent clinical trials demonstrate significant improvements in neurological function with clot retrieval therapies, increasing recovery rates to 40-50%. However, implementation into practice requires concentrated effort from multiple parties, including training and education.
A new study found that TAVI is safe and effective as a surgical alternative for selected lower-risk patients, with comparable outcomes at two years. The Nordic Aortic Valve Intervention (NOTION) trial showed no significant difference in mortality rates between TAVI and surgical valve replacement.
The 'Radial Paradox' reveals that radial access may offset vascular complications when used as a backup method for femoral access. A study found that non-culprit vessels with significant stenosis are not functionally important, increasing debate on intervention strategy. Meanwhile, elderly patients benefit from drug-eluting stents with...
The SYMPLICITY-HTN-3 clinical trial confirmed the safety of renal denervation, but questions remain about its efficacy in patients with difficult-to-control hypertension. Further research is needed to identify the best patients who will benefit from treatment with the procedure.
The ACCOAST trial data showed that pre-treatment with prasugrel in NSTEMI patients undergoing PCI was inferior to treatment after angiography, but the results did not change practitioners' current practice. The new session format aims to translate clinical trial science into daily practice.
Experts discussed bioresorbable vascular scaffolds' potential to restore normal vasofunction and promote vascular healing. However, concerns remain regarding acute thrombogenicity, delayed endothelialisation, and uncertainty around long-term safety data.
The EuroPCR panel stresses the importance of personalizing revascularization strategies for STEMI patients. Primary percutaneous coronary intervention (PCI) is considered the gold standard, but its availability can be limited in resource-scarce environments, making thrombolysis a viable alternative.
Leadless pacemakers with seven-to-ten-year battery life have shown significant advancements in reliability and reduced risk of infection and thromboembolic complications. Transcatheter aortic heart valve developments also showcased improved outcomes with no reported cases of severe paravalvular leak.
The first PCR Innovation Day brought together key stakeholders to address unmet clinical needs in interventional cardiovascular medicine. This event provided an opportunity for physicians, inventors, and entrepreneurs to network and discuss innovative technologies.